{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:02:32Z","timestamp":1770062552763,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1006\/clim.2000.4920","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:45:11Z","timestamp":1032191111000},"page":"109-120","source":"Crossref","is-referenced-by-count":41,"title":["Immune Stimulation in Scleroderma Patients Treated with Thalidomide"],"prefix":"10.1006","volume":"97","author":[{"given":"Stephen J.","family":"Oliver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilla","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/clim.2000.4920_RF1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00002281-199511000-00014","article-title":"Clinical aspects of systemic and localized scleroderma","volume":"7","author":"van den Hoogen","year":"1995","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1006\/clim.2000.4920_RF2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0889-857X(05)70296-9","article-title":"Immunopathogenesis of systemic sclerosis","volume":"22","author":"White","year":"1996","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1006\/clim.2000.4920_RF3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0090-1229(92)90158-K","article-title":"Cytokine production and serum levels in systemic sclerosis","volume":"65","author":"Kantor","year":"1992","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1006\/clim.2000.4920_RF4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780350111","article-title":"Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma","volume":"35","author":"Needleman","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2000.4920_RF5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2249.1992.tb03074.x","article-title":"In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases","volume":"88","author":"Prior","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"10.1006\/clim.2000.4920_RF6","first-page":"1751","article-title":"Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1006\/clim.2000.4920_RF7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","article-title":"Sequential dermal microvascular and perivascular changes in the development of scleroderma","volume":"166","author":"Prescott","year":"1992","journal-title":"J. Pathol."},{"key":"10.1006\/clim.2000.4920_RF8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780270607","article-title":"Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations","volume":"27","author":"Roumm","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2000.4920_RF9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.1990.tb05340.x","article-title":"Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis","volume":"81","author":"Famularo","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1006\/clim.2000.4920_RF10","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1006\/clim.2000.4920_RF11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/clin.1993.1100","article-title":"Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis","volume":"68","author":"Sfikakis","year":"1993","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1006\/clim.2000.4920_RF12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2230.1983.tb01820.x","article-title":"Scleroderma-like changes due to chronic graft-versus-host disease","volume":"8","author":"Graham-Brown","year":"1983","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-87-6-707","article-title":"Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease","volume":"87","author":"Lawley","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2000.4920_RF14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00002281-199811000-00010","article-title":"Microchimerism and the pathogenesis of systemic sclerosis","volume":"10","author":"Nelson","year":"1998","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1006\/clim.2000.4920_RF15","series-title":"Graft-vs-Host Diseases","article-title":"The immune system: effector and target of graft-versus-host disease","author":"Hakim","year":"1997"},{"key":"10.1006\/clim.2000.4920_RF16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":"Thalidomide for the treatment of chronic graft-versus-host disease","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2000.4920_RF17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00007890-198605000-00018","article-title":"Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model","volume":"41","author":"Vogelsang","year":"1986","journal-title":"Transplantation"},{"key":"10.1006\/clim.2000.4920_RF18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V74.1.507.507","article-title":"Therapy of chronic graft-v-host disease in a rat model","volume":"74","author":"Vogelsang","year":"1989","journal-title":"Blood"},{"key":"10.1006\/clim.2000.4920_RF19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol. Med."},{"key":"10.1006\/clim.2000.4920_RF21","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2000.4920_RF23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2000.4920_RF24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780380309","article-title":"Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis","volume":"38","author":"White","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2000.4920_RF25","series-title":"Leprosy","first-page":"193","author":"Jacobson","year":"1985"},{"key":"10.1006\/clim.2000.4920_RF26","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1006\/clim.2000.4920_RF27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/aid.1997.13.1047","article-title":"The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus","volume":"13","author":"Haslett","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1006\/clim.2000.4920_RF28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(98)70513-4","article-title":"Recalcitrant pyoderma gangrenosum: treatment with thalidomide","volume":"38","author":"Hecker","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0190-9622(08)80705-0","article-title":"Pyoderma gangrenosum associated with Behcet's disease: treatment with thalidomide","volume":"23","author":"Rustin","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF30","first-page":"408","article-title":"Pyoderma gangrenosum associated with Behcet's syndrome\u2014response to thalidomide","volume":"13","author":"Munro","year":"1988","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2000.4920_RF32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","article-title":"Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2000.4920_RF33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1046\/j.1523-1747.1999.00744.x","article-title":"Thalidomide increases human keratinocyte migration and proliferation","volume":"113","author":"Nasca","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.168.4.1395","article-title":"Keratinocyte growth regulation by the products of immune cells","volume":"168","author":"Hancock","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.175.6.1717","article-title":"Novel responses of human skin to intradermal recombinant granulocyte\/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing","volume":"175","author":"Kaplan","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/1523-1747.ep12396936","article-title":"GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo","volume":"103","author":"Braunstein","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1524-475X.1999.00017.x","article-title":"Randomized, double-blind, placebo-controlled, dose- ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers","volume":"7","author":"Da Costa","year":"1999","journal-title":"Wound Repair Regen."},{"key":"10.1006\/clim.2000.4920_RF38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2133.2000.03263.x","article-title":"Successful treatment of aphthous ulcerations in AIDS patients using topical granulocyte-macrophage colony-stimulating factor","volume":"142","author":"Herranz","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1006\/clim.2000.4920_RF40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4049\/jimmunol.158.1.359","article-title":"Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40","volume":"158","author":"DeKruyff","year":"1997","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2000.4920_RF41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V86.6.2429.bloodjournal8662429","article-title":"Interleukin-12 inhibits murine graft-versus-host disease","volume":"86","author":"Sykes","year":"1995","journal-title":"Blood"},{"key":"10.1006\/clim.2000.4920_RF42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.189.2.219","article-title":"Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis","volume":"189","author":"Tarrant","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF43","first-page":"823","article-title":"Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents","volume":"37","author":"Fertin","year":"1991","journal-title":"Cell. Mol. Biol."},{"key":"10.1006\/clim.2000.4920_RF44","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2619::AID-IMMU2619>3.0.CO;2-M","article-title":"Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma","volume":"28","author":"Ong","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1006\/clim.2000.4920_RF45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1084\/jem.162.2.516","article-title":"Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation","volume":"162","author":"Duncan","year":"1985","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2000.4920_RF46","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI111480","article-title":"Selective inhibition of human diploid fibroblast collagen synthesis by interferons","volume":"74","author":"Jimenez","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1006\/clim.2000.4920_RF47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/1523-1747.ep12319207","article-title":"Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures","volume":"109","author":"Serpier","year":"1997","journal-title":"J. Invest. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archderm.1997.03890410093013","article-title":"Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically?","volume":"133","author":"Varga","year":"1997","journal-title":"Arch. Dermatol."},{"key":"10.1006\/clim.2000.4920_RF49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2133.1998.02460.x","article-title":"Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial","volume":"139","author":"Grassegger","year":"1998","journal-title":"Br. J. Dermatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661600949209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661600949209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T20:15:21Z","timestamp":1680552921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661600949209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S1521661600949209"],"URL":"https:\/\/doi.org\/10.1006\/clim.2000.4920","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}